Cannabidiol
CBD
Non-intoxicating. The only cannabis-derived compound with an FDA-approved medicine behind it, and the cannabinoid most often used to soften THC.
Evidence status
Strong RCT evidence exists for specific seizure disorders (basis of the Epidiolex approval). For anxiety, NASEM 2017 found only limited evidence, and that was for CBD in a public-speaking test in social anxiety disorder. Consumer claims about CBD for pain and sleep run well ahead of the evidence.
CBD does not bind CB1 receptors the way THC does, which is why it is not intoxicating. Its mechanisms are more diffuse and less well characterised, involving serotonin receptors, TRPV1 channels, and modulation of the endocannabinoid system indirectly.
Epidiolex, a purified plant-derived CBD oral solution, was approved by the FDA in June 2018 and is currently indicated for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients one year of age and older. That is a narrow, specific indication — it is not evidence that CBD treats pain, anxiety, or sleep.
For most consumer uses, CBD is best understood as a modifier rather than a primary treatment. Products with meaningful CBD alongside THC tend to be more tolerable for people who find THC alone too intense, though the mechanism for that is not settled.
CBD is pharmacologically active enough to matter for drug interactions. The current Epidiolex label lists inhibition of CYP2C19, CYP2C8, UGT1A9, and weak CYP1A2 inhibition, and flags P-glycoprotein substrates including everolimus, sirolimus, tacrolimus, and digoxin.
Commonly used for
- • Specific seizure disorders (prescription Epidiolex only)
- • Reducing the intensity of THC
- • Social anxiety (limited evidence)
Cautions
- • Clinically meaningful drug interactions — check with a pharmacist if you take prescription medication.
- • Increases plasma concentrations of N-desmethylclobazam roughly threefold when taken with clobazam.
- • Can cause dose-related liver enzyme elevations, particularly with valproate.
- • FDA has not approved CBD as a dietary supplement or food additive.
Conditions where CBD is part of the suggested profile
- Chronic painPain lasting more than three months. The single indication with the strongest evidence base for cannabis in adults.
- Multiple sclerosis spasticityMuscle stiffness and spasm in multiple sclerosis. Substantial evidence for patient-reported improvement; weaker for clinician-measured.
- Sleep disturbanceDifficulty falling or staying asleep. Moderate evidence — but only for sleep disturbance tied to specific underlying conditions.
- Social anxietyAnxiety in social or performance situations. Limited evidence for CBD specifically — and THC often makes anxiety worse.
- PTSDPost-traumatic stress disorder. Limited evidence resting on a single small trial — and a qualifying condition in many state medical programs regardless.
- FibromyalgiaWidespread pain with fatigue and sleep disruption. Covered indirectly by the chronic pain and sleep findings.
- Neuropathic painPain from nerve damage — burning, shooting, or electric in quality. Covered by the chronic pain finding.
- ArthritisJoint pain and inflammation. Covered by the chronic pain finding.
- MigraineRecurrent severe headache. Insufficient evidence specifically for migraine, despite widespread claims.
- Generalised anxietyPersistent anxiety not tied to social situations. Insufficient evidence, and THC can make it worse.
- DepressionPersistent low mood. NASEM found limited evidence that cannabinoids are INEFFECTIVE for depression in chronic pain and MS.
- Muscle spasmsInvoluntary muscle contraction. Evidence is strongest in MS spasticity; weaker for spasms from other causes.
- InflammationInflammatory processes. Mechanistically plausible via CB2, but not clinically established in humans.
- IBS and inflammatory bowel diseaseDigestive conditions with pain and disrupted bowel function. Symptom relief may help; disease activity does not appear to change.
- Epilepsy and seizure disordersPrescription CBD has strong RCT evidence in three specific syndromes. Dispensary products do not.
- Menstrual crampsPainful periods. No condition-specific evidence; covered loosely by chronic pain.
- Back painPersistent back pain. Covered by the chronic pain finding once it is chronic.
- Cancer-related painPain associated with cancer or its treatment. Covered by chronic pain; cannabis does not treat cancer.
- Parkinson's diseaseMovement disorder. NASEM found no or insufficient evidence.
Sources
- Epidiolex (cannabidiol) oral solution, prescribing information, revised 05/2026. NDA 210365.Accessed 2026-08-15.
- U.S. Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD).Accessed 2026-08-15.
- NASEM 2017, Committee Conclusions (summary PDF of all evidence-tier conclusions).Accessed 2026-08-15.